<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Puma Biotechnology Inc

    Puma Biotechnology Inc

    Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...

    Puma Biotechnology, Inc. is a biopharmaceutical...

    Filing Type:    PU
    Aytu BioScience, Inc.

    Aytu BioScience, Inc.

    Aytu is committed to better health for men and women here at home and worldwide. W...

    Aytu is committed to better health for men and ...

    Filing Type:    PU
    Alpine Immune Sciences, Inc.

    Alpine Immune Sciences, Inc.

    Alpine is a development-stage specialty pharmaceutical company focused on discover...

    Alpine is a development-stage specialty pharmac...

    Filing Type:    PU
    Immutep Limited

    Immutep Limited

    We are a biotechnology company developing novel immunotherapy treatments for cance...

    We are a biotechnology company developing novel...

    Filing Type:    PU
    Precision BioSciences, Inc.

    Precision BioSciences, Inc.

    Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...

    Precision BioSciences is dedicated to improving...

    Filing Type:    PU
    Siemens Healthineers AG

    Siemens Healthineers AG

    Siemens Healthineers AG is the holding company of the Siemens Healthineers group. ...

    Siemens Healthineers AG is the holding company ...

    Filing Type:    PU
    Equillium, Inc.

    Equillium, Inc.

    Equillium is a biotechnology company leveraging deep understanding of immunobiolog...

    Equillium is a biotechnology company leveraging...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Celyad SA

    Celyad SA

    Celyad is a biopharmaceutical company, specialized in CAR-T cell therapy, that is ...

    Celyad is a biopharmaceutical company, speciali...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.